Novartis is exploring a diverse portfolio of new isotopes, ligands and combination therapies to expand the use of RLTs in additional cancer types beyond prostate and neuroendocrine tumors EAST HANOVER ...

Novartis on Wednesday announced it has begun construction on two radioligand therapy manufacturing facilities in a bid to beef up supply of its products Pluvicto and Lutathera—and solidify its ...

Regulatory Approvals: Recent regulatory approvals for Novartis’s radioligand products, such as Lutathera and Pluvicto, have paved the way for broader market acceptance. With these products gaining ...

Novartis (OTCPK:NVSEF) is a dominant force in the RLT space, with radiopharmaceuticals such as Pluvicto and Lutathera in its portfolio. The company said that following regulatory clearances ...

Novartis is exploring a diverse portfolio of new isotopes, ligands and combination therapies to expand the use of RLTs in additional cancer types beyond prostate and neuroendocrine tumors EAST ...

Built on the success of the neuroendocrine tumor drug Lutathera and the prostate cancer drug Pluvicto, radioligand therapy is a key area of focus for Novartis. The Swiss pharma has invested ...

Yet the way the PDC Order of Merit rankings are formulated means he is still quite a way down their list. They are based on the "prize money won in ranking tournaments over a two-year period".

Novartis was the first to scale the availability of RLTs in the market across different cancer types with Pluvicto® (lutetium Lu 177 vipivotide tetraxetan) and Lutathera® (lutetium Lu 177 dotatate).

EAST HANOVER, N.J., Sept. 4, 2024 /PRNewswire/ -- Novartis today announced the construction of two new radioligand therapy (RLT) manufacturing facilities in the US that will extend its world-class ...